Julia Dai, MD

Articles by Julia Dai, MD

10 Experts Predict the Future of CTCL Treatment

10 Experts Predict the Future of CTCL Treatment

ByJan P. Nicolay, MD, PhD,Gabriele Roccuzzo, MD,Marie Beylot-Barry, MD, PhD,H. Miles Prince, MD, MBBS,Lena Specht, MD, DMSc,Neha Mehta-Shah, MD, MSCI,Julia Dai, MD,Oleg Akilov, MD, PhD,Stefan K. Barta, MD, MS,Christiane Querfeld, MD, PhD

June 30th 2026

At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.

Latest Updated Articles

Trending on OncLive

FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma

Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma

The OncFive: Top Oncology Articles for the Week of 8/9

FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma

Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC